Physician profile
Iman Ali
NPI 1164466272
$3,715.76
in general payments reported to CMS, 2019-2025
14 companies · $636 in 2025
The $636 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $289 · 2021: $218 · 2022: $646 · 2023: $358 · 2024: $667 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,660.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $726.43 | 2019-2025 | Rinvoq |
| Glaxosmithkline, LLC. | $516.45 | 2019-2023 | Benlysta |
| Pfizer INC. | $451.91 | 2019-2024 | |
| Amgen INC. | $407.57 | 2019-2025 | Tavneos |
| Ucb, INC. | $330.22 | 2022-2024 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $264.00 | 2019-2025 | |
| Horizon Therapeutics Plc | $246.46 | 2019-2020 | |
| Lilly USA, LLC | $222.40 | 2019-2023 | Taltz |
| Astrazeneca Pharmaceuticals Lp | $181.09 | 2022-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $165.14 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $95.27 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $51.63 | 2019 | |
| Alexion Pharmaceuticals, INC. | $42.51 | 2025 | Ultomiris |
| Novo Nordisk INC | $14.68 | 2025 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iman Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.